Eli Lilly Presents New Exploratory Data From The TOGETHER-PSO Phase 3B Clinical Trial Taltz And Zepbound Compared With Taltz Alone In Adults With Moderate-To-Severe Plaque Psoriasis And Obesity Or Overweight; Data Showed Broader Biomarker Changes With Taltz And Zepbound Vs Taltz Alone

Loading news article.

Eli Lilly Presents New Exploratory Data From The TOGETHER-PSO Phase 3B Clinical Trial Taltz And Zepbound Compared With Taltz Alone In Adults With Moderate-To-Severe Plaque Psoriasis And Obesity Or Overweight; Data Showed Broader Biomarker Changes With Taltz And Zepbound Vs Taltz Alone | WAPE

Eli Lilly Presents New Exploratory Data From The TOGETHER-PSO Phase 3B Clinical Trial Taltz And Zepbound Compared With Taltz Alone In Adults With Moderate-To-Severe Plaque Psoriasis And Obesity Or Overweight; Data Showed Broader Biomarker Changes With Taltz And Zepbound Vs Taltz Alone

Article summary

Related companies

Comments —